Thalassemia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Thalassemia Treatment Market Growth & Share. The market is segmented by Treatment Type (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Others), by Disease Type, by End-User and by Geography.

Thalassemia Treatment Market Size

Single User License
Team License
Corporate License
Book before:
Thalassemia treatment Market Size
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 7.60 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Thalassemia treatment Market Key Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Thalassemia Treatment Market Analysis

The thalassemia treatment market studied was projected to grow with a CAGR of nearly 7.6% over the forecast period. The major factors attributing to the growth of the market are increasing prevalence of thalassemia and also growing awareness to treat thalassemia. According to National Center on Birth Defects and Developmental Disabilities, thalassemia, affects at least 1,000 people in the United States. Furthermore the growing  investements in research and development programs by the biotechnology and pharmaceutical companies boosting the market growth. Chelation therapy and blood transfusion are the conventional treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion method for purifying blood, raise the possibility of curing thalassemia in patients. However the high cost of the treatment is major drawback for the market growth.

Thalassemia Treatment Market Trends

This section covers the major market trends shaping the Thalassemia Treatment Market according to our research experts:

Chelation Therapy segment is expected to be the Fastest Growing Segment

  • Iron overload is the main cause of sickness for thalassemia patients. Even non- transfused patients develop iron overload secondary to boosted intestinal absorption of dietary iron. Iron overload is a leading cause of mortality and organ injury. The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow transplantation.
  • The segment is projected to expand at an exponential growth rate during the forecast period. The major factors driving the growth of the segment are increasing incidence of thalassemia patients and increasing research and development investments.
Thalassemia treatment Market Share

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall thalassemia treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of thalassemia patients in the region and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. The United States has the main share due to the rising awareness about the condition and increasing number of populations with thalassemia carrier gene, and growth in birth rates due to variation of genes among the population.

Thalassemia treatment Market Growth

Thalassemia Treatment Industry Overview

The thalassemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.,

Thalassemia Treatment Market Leaders

  1. Bluebird Bio

  2. Novartis AG

  3. ApoPharma Inc

  4. Bellicum Pharmaceuticals

  5. Pfizer, Inc.

*Disclaimer: Major Players sorted in no particular order

Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.
bookmark Need More Details on Market Players and Competitors?
Download PDF

Thalassemia Treatment Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Thalassemia

      2. 4.2.2 Increasing Awareness of Thalassemia Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Blood Transfusions

      2. 5.1.2 Iron Chelation Therapy

      3. 5.1.3 Folic Acid Supplements

      4. 5.1.4 Others

    2. 5.2 By Disease Type

      1. 5.2.1 Alpha Thalassemia

      2. 5.2.2 Beta Thalassemia

    3. 5.3 By End-User

      1. 5.3.1 Hospitals

      2. 5.3.2 Research Institutes

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bluebird Bio

      2. 6.1.2 IONIS Pharmaceuticals

      3. 6.1.3 Novartis AG

      4. 6.1.4 Bellicum Pharmaceuticals

      5. 6.1.5 ApoPharma Inc

      6. 6.1.6 Pfizer, Inc.

      7. 6.1.7 Acceleron Pharma, Inc.

      8. 6.1.8 Kiadis Pharma

      9. 6.1.9 SG Phrma Pvt. Lmt.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Thalassemia Treatment Industry Segmentation

As per the scope of the report thalassemia is a blood disorder passed down through families in which the body makes an abnormal form or insufficient amount of hemoglobin. This report is segmented by Treatment Type, by Disease Type, by End-User, and by Geography.

By Treatment Type
Blood Transfusions
Iron Chelation Therapy
Folic Acid Supplements
Others
By Disease Type
Alpha Thalassemia
Beta Thalassemia
By End-User
Hospitals
Research Institutes
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Thalassemia Treatment Market Research FAQs

The Thalassemia Treatment Market is projected to register a CAGR of 7.60% during the forecast period (2024-2029)

Bluebird Bio, Novartis AG, ApoPharma Inc, Bellicum Pharmaceuticals and Pfizer, Inc. are the major companies operating in the Thalassemia Treatment Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Thalassemia Treatment Market.

The report covers the Thalassemia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Thalassemia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Thalassemia Treatment Industry Report

Statistics for the 2024 Thalassemia Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Thalassemia Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Thalassemia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)